Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival
Ezgi Ozyerli‐Goknar(Koç University), Tugba Bagcı-Önder(Koç University), Sonia H.Y. Kung(BC Cancer Agency), Mehmet Gönen(Sage Bionetworks), Tamer T. Önder(Koç University), İpek Bulut(Koç University), Adam P. Cribbs(Centre for Human Genetics), Nurcan Tunçbağ(Massachusetts Institute of Technology), Ali Cenk Aksu(Koç University), Can Aztekin(Max Planck Society), Hamzah Syed(Koç University), Ceyda Açılan(Koç University), Tunç Morova(Koç University), Ahmet Cingöz(Koç University), Ezgi Yağmur Kala(Koç University), Martin Philpott(Nuffield Orthopaedic Centre), Sheikh Nizamuddin(Centre for Cellular and Molecular Biology), Martin L. Biniossek(University of Freiburg), Fidan Seker-Polat(Koç University), H. T. Marc Timmers(University of Freiburg), Nathan A. Lack(Koç University)
Cited by 0
Related Papers
Chromatin-modifying enzymes as modulators of reprogramming
|Nature|2012|635
Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids
|Cell stem cell|2021|311
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
|Molecular Cancer|2016|261
Apoptosis: why and how does it occur in biology?
|Cell Biochemistry and Function|2011|227